Evidence map›Paper›PMID 28755385›Full record

ArticleDiabetes/metabolism research and reviews2017

Building and validating a prediction model for paediatric type 1 diabetes risk using next generation targeted sequencing of class II HLA genes.

Lue Ping Zhao, Annelie Carlsson, Helena Elding Larsson, Gun Forsander, Sten A Ivarsson, Ingrid Kockum, Johnny Ludvigsson, Claude Marcus, Martina Persson, Ulf Samuelsson and 8 more

Erratum issuedAbstract readValidation Study
PubMed Full text at PMC Publisher
In one paragraph

Article in Diabetes/metabolism research and reviews, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Human CD4Cancer immunology research · 2019
    Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

18 authors.

Lue Ping ZhaoDivision of Public Health Sciences, Fred Hutchinson Cancer Research Center, Seattle, WA, USA.ORCID 0000-0002-1387-7165
Annelie CarlssonDepartment of Pediatrics, Lund University, Lund, Sweden.
Helena Elding LarssonDepartment of Clinical Sciences, Lund University/CRC, Skåne University Hospital, Malmö, Sweden.
Gun ForsanderInstitute of Clinical Sciences, Department of Pediatrics and the Queen Silvia Children's Hospital, Sahlgrenska University Hospital, Gothenburg, Sweden.
Sten A IvarssonDepartment of Clinical Sciences, Lund University/CRC, Skåne University Hospital, Malmö, Sweden.
Ingrid KockumDepartment of Clinical Neurosciences, Karolinska Institutet, Solna, Sweden.
Johnny LudvigssonDepartment of Clinical and Experimental Medicine, Linköping University, Linköping, Sweden.
Claude MarcusDepartment of Clinical Science, Karolinska Institutet, Huddinge, Sweden.
Martina PerssonDepartment of Medicine, Clinical Epidemiology, Karolinska University Hospital, Solna, Sweden.
Ulf SamuelssonDepartment of Clinical and Experimental Medicine, Linköping University, Linköping, Sweden.
Eva ÖrtqvistDepartment of Medicine, Clinical Epidemiology, Karolinska University Hospital, Solna, Sweden.
Chul-Woo PyoClinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA.
Hamid BolouriSchool of Arts and Sciences, University of Washington, Seattle, WA, USA.
Michael ZhaoSchool of Arts and Sciences, University of Washington, Seattle, WA, USA.
Wyatt C NelsonClinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA.
Daniel E GeraghtyClinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA.
Åke LernmarkDepartment of Clinical Sciences, Lund University/CRC, Skåne University Hospital, Malmö, Sweden.
Better Diabetes Diagnosis (BDD) Study Group

Funding

The Environmental Triggers of Diabetes (TEDDY) in SwedenU01DK063861 · NIDDK · UNIVERSITY OF WASHINGTON · PI LERNMARK, AKE · 2003 to 2022
$13.4M
The Environmental Triggers of Diabetes (TEDDY)UC4DK063861 · NIDDK · LUNDS UNIVERSITET · PI LERNMARK, AKE · 2013 to 2013
$5.7M
ISLET CELL MEMBRANE ANTIBODIES IN DIABTESR01DK026190 · NIDDK · UNIVERSITY OF WASHINGTON · PI HAMPE, CHRISTIANE S · 1986 to 2016
$4.9M
Methods for Correlating SNP Haplotypes with CancerR01CA106320 · NCI · FRED HUTCHINSON CANCER RESEARCH CENTER · PI ZHAO, LUE PING · 2004 to 2008
$1.9M
NCI NIH HHS R01 CA106320NIDDK NIH HHS R01 DK026190NIDDK NIH HHS U01 DK063861NIDDK NIH HHS UC4 DK063861
6 · The paper itself

Abstract

aimIt is of interest to predict possible lifetime risk of type 1 diabetes (T1D) in young children for recruiting high-risk subjects into longitudinal studies of effective prevention strategies.

methodsUtilizing a case-control study in Sweden, we applied a recently developed next generation targeted sequencing technology to genotype class II genes and applied an object-oriented regression to build and validate a prediction model for T1D.

resultsIn the training set, estimated risk scores were significantly different between patients and controls (P = 8.12 × 10

conclusionThrough both empirical and biological validation, we have established a prediction model for estimating lifetime T1D risk, using class II HLA. This prediction model should prove useful for future investigations to identify high-risk subjects for prevention research in high-risk populations.

Indexed as

AutoantibodiesGenetic Predisposition to DiseaseAllelesCase-Control StudiesChildDiabetes Mellitus, Type 1FemaleGenotypeHLA-DQ AntigensHumansMaleModels, TheoreticalRisk AssessmentRisk FactorsSwedenAutoantibodiesHLA-DQ Antigensautoimmune diseasegeneticsgenome-wide association studyislet autoantibodiesobject-oriented regressiontype 1 diabetes

Identifiers

PMID28755385
PMCPMC11587868

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.